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HLA-G and Immune Evasion in Cancer Cells
Jim Sheu,1,2,3 Ie-Ming Shih1*
Acquisition of novel gene products or new antigens in cancer cells elicits a host immune response that
results in selection pressure for tumor clones to evade immunosurveillance. Similar to maternal–fetal
tolerance and allotransplantation acceptance, upregulation of HLA-G expression has been found as one
of the mechanisms that are programmed in cancer cells. HLA-G expression is frequently detected in a
wide variety of human cancers and its protein levels negatively correlate with poor clinical outcome.
The immune inhibitory effect can be achieved by binding of HLA-G molecules to the immunoglobulin-
like inhibitory receptors that are expressed on the immunocompetent cells at all stages of the immune
response. This review summarizes recent studies of HLA-G expression in human cancer, with a special
focus on the molecular mechanisms that underlie how HLA-G molecules facilitate tumor cell evasion
of the host immune response, and presents new directions for developing HLA-G-based diagnosis/
therapeutics.
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In normal human tissues, constitutive HLA-G 
expression is restricted to a few tissue types, in-
cluding trophoblastic cells and thymic epithe-
lium.1–3 The identification of HLA-G expression
in trophoblasts and its role in suppressing local
immunity in the placenta suggest that cancer cells
employ HLA-G overexpression during tumor 
development to help evade host immunosurveil-
lance; a strategy that is similar to that of tro-
phoblastic at the maternal–fetal interface. Indeed,
HLA-G expression has been detected in a wide
variety of human cancers, including cutaneous
melanoma, lung carcinoma, ovarian carcinoma,
endometrial carcinoma, gastric carcinoma, hema-
topoietic tumors, renal cell carcinoma, mesothe-
lioma, breast carcinoma, trophoblastic tumors,
glioma, bladder carcinoma, and colorectal carci-
noma, and lymphoproliferative disorders.3–11 In
addition, the soluble form of HLA-G (sHLA-G) can
also be detected in the supernatant of body fluids
or malignant effusions in cancer patients.7,12–16
These studies have important biological and clini-
cal implications for HLA-G expression in human
tumor tissues. The above tumor types might only
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represent a short list and more human cancers
with HLA-G expression will be reported as research
progresses.
This review summarizes those recent studies of
HLA-G expression in human cancer, with a special
emphasis on the molecular mechanisms of how
HLA-G molecules inactivate immune effectors.
Understanding the HLA-G-regulated immune 
response is fundamental to elucidation of the
molecular mechanisms in cancer development
and lays the foundation for future therapeutics
by targeting HLA-G and related molecules.
HLA-G is a Distinct Major 
Histocompatibility Complex (MHC) 
Class I Molecule
HLA-G is a unique, non-classical (class Ib) MHC
class I molecule and, like other class I MHC pro-
teins, it is composed of a membrane-bound heavy
chain and a nonameric peptide that associate with
each other via a non-covalent protein–protein
interaction. The heavy chain of HLA-G requires
association with the β2m molecule for its expor-
tation to the cell surface and for binding to 
HLA-G ligands.1,17 Although the HLA-G gene is
located in the HLA-1 locus of human chromo-
some 6 and shares several similar characteristics
with other MHC class I molecules, its expression
pattern, peptide binding properties, and im-
munological functions are different. More im-
portantly, the expression levels of classical MHC
molecules (class Ia), HLA-A, HLA-B and HLA-C,
are usually downregulated in tumor cells. This
indicates different patterns of expression of the
various classes of MHC molecules in the develop-
ment of human cancer, which might act in con-
cert for the tumor-associated immunosuppressive
phenotype.18,19
Protein structure analyses demonstrate that the
membrane bound heavy chain of HLA-G contains
three immunoglobulin-like domains (α1–α3) 
in which the α1 and α2 domains constitute the
peptide-binding cleft. For the classical (class Ia)
MHC molecules, the peptide-binding regions 
are characterized by extensive amino acid poly-
morphism, which creates a diverse repertoire for
peptide-loading and T-cell recognition.20 In con-
trast, non-classical HLA molecules such as HLA-
G contain limited polymorphism, which results
in a restricted number of peptides that are capa-
ble of binding to HLA-G.21,22 To date, only three
peptides have been isolated and characterized
from placenta-derived HLA-G molecules,23 and
other HLA-G binding peptides remain to be
identified from human cancer cells.
In addition, unlike classical MHC class I mol-
ecules, HLA-G appears inefficient at presenting
exogenous peptides because it does not contain
most of the intracellular portion that other MHC
class I proteins do.24 The structural uniqueness
of HLA-G is therefore translated to its distinct 
biological features in cellular functions. For ex-
ample, HLA-G functions as a common ligand for
inhibitory receptors on immune effectors, thus
participating in immune regulation. It has also
been shown that the identity of the peptide on
the peptide-binding cleft affects the binding of
HLA-G to killer cell immunoglobulin-like recep-
tor (KIR).25 Another feature unique to HLA-G
which is not shared by other MHC molecules 
is its homodimerization to form the cys42–
cys42 disulfide-linked complexes.26,27 Dimerized
HLA-G proteins, in contrast to the monomeric
form, have a higher protein stability and confer a
higher affinity to the inhibitory receptors, which
in turn can contribute to more potent immuno-
suppression in immune effector cells.17,26–28
Clinical Evidence of HLA-G in
Immunosuppression
Clinical evidence in support of the role of HLA-G
in immunosuppression primarily comes from
studies that have focused on correlating HLA-G
expression levels and clinical outcome in preg-
nancy and organ transplantation, which represent
two major conditions for a host response to non-
self tissues. In pregnancy, it is accepted that ma-
ternal immunotolerance to the “semi-allograft”,
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that is, fetus and placenta, is attributed to the
presence of HLA-G. The fact that trophoblast
cells in human placenta express a very high level
of HLA-G suggests its involvement in regulating
immune reactions at the fetal–maternal interface.
Secretion of sHLA-G by the early conceptus ap-
pears to be essential for successful implantation,
and it has been used as a reliable marker of in-
creased subsequent pregnancy following in vitro
fertilization.15,29–31 The presence of HLA-G tran-
scripts in preimplantation embryos is correlated
with increased blastocystic cleavage rate and a
greater number of blastomeres per embryo fol-
lowing in vitro fertilization.32 In contrast, the abor-
tion rate increases for women who have previously
received embryos with low or undetectable HLA-G
expression.31 A null HLA-G allele in a conceptus
is also associated with recurrent miscarriage in
women.33,34
Allogeneic organ transplantation is always 
rejected by the host immune surveillance system
unless immunosuppressive reagents are adminis-
tered to protect the grafted tissues. sHLA-G is usu-
ally detected at high levels in blood samples from
transplantation patients whose grafted tissues
survive.35 In addition, HLA-G-positive infiltrat-
ing monocytes are observed in the grafted tissues
due to the binding of sHLA-G to its receptor on
the immune cells. The finding of the above clini-
cal correlation studies are consistent with the view
that HLA-G expression plays an important role
in immunosuppressive functions in pregnancy
and allograft rejection. It is very likely that simi-
lar molecular mechanisms also are used by cancer
cells to evade host immunosurveillance.
Variant Forms of HLA-G in 
Human Cancer
In addition to the membrane-bound form of
HLA-G, increased plasma levels of sHLA-G have
been detected in patients with malignant tumors.
These findings suggest that HLA-G participates in
the immune response and networking via direct
cell–cell contact and through secretion of sHLA-G
(Figure 1). Clinical studies on tumor specimens
have demonstrated that monomeric and dimeric
sHLA-G can be detected in body fluids, including
serum and effusion samples, and sHLA-G shares
similar biological functions with the membrane-
bound form. These findings could explain why
only a small percentage of tumor cells show pos-
itive HLA-G staining in human tumor tissues. By
secreting sHLA-G that diffuses into deeper tissues,
tumor cells still can inactivate the local immune
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Figure 1. HLA-G variants and protection of cancer cells from immunosurveillance. (A) HLA-G variants are produced by
alternative splicing. Splicing variants HLA-G1 to G4 contain the entire transmembrane domain and the intracellular tail,
thus forming membrane-bound HLA-G on the surface of cancer cells. Splicing variants HLA-G5 to G7 are secreted forms
of HLA-G, thus functioning as soluble HLA-G (sHLA-G) to block immune recognition and targeting. (B) Immune effector
cells proceed to inactivation or cell death after binding to membrane-bound or sHLA-G. Although not all of the cancer
cells express HLA-G, sHLA-G from HLA-G-positive cells can still protect them from immunosurveillance.
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response, even for those bystanders without HLA-
G expression on the cell surface.
Production of sHLA-G can be achieved by
mRNA splicing. In fact, seven different HLA-G
isoforms have been reported and they are found
in a tissue-specific expression pattern. These iso-
forms include four membrane-bound HLA-Gs
(HLA-G1 to G4) and three sHLA-Gs (HLA-G5 to
G7). HLA-G1 represents the full-length version
of HLA-G and contains a signal peptide (exon 1);
the α1, α2 and α3 domains (exons 2–4, respec-
tively); the transmembrane domain (exon 5); and
a short intracellular domain (exons 6 and 7). HLA-
G2, as compared with HLA-G1, does not contain
exon 3, and HLA-G3 does not contain exons 3
and 4, whereas HLA-G4 does not contain exon 4.
Isoforms HLA-G5 to G7 retain a portion of in-
tron 4 that contains a stop codon, which results
in expression of truncated (without exon 5 trans-
membrane domain) or soluble forms that corre-
spond to HLA-G1 to G3, respectively.
Factors Involved in Regulation of HLA-G
Expression in Tumors
The molecular mechanisms that upregulate
HLA-G expression in tumor cells are complex.
They involve several factors including epigenetic
control of the HLA-G promoter activation and a
variety of environmental factors such as hypoxia,
stress, hormones, certain cytokines, and viral in-
fection. Sequence analysis of the HLA-G gene
promoter reveals that almost all regulatory boxes
described for classical MHC class I genes are not
conserved in the HLA-G promoter.4 This finding
suggests that the mechanisms involved in the
transcriptional regulation of HLA-G expression
are unique and partly independent of those that
regulate classical HLA-class I genes.
Recent studies have demonstrated that HLA-G
gene transcription activity can be controlled 
by cis-acting epigenetic mechanisms that include
DNA methylation and histone acetylation.36 For
example, primary tumor cells in culture gradu-
ally decrease HLA-G expression, and cells treated
with histone deacetylase inhibitors or DNA
demethylating agents re-express HLA-G by re-
versing the promoter silencing.4 The epigenetic
regulation is even more pronounced under cer-
tain microenvironmental conditions, such as hy-
poxia, which is a common phenomenon in solid
tumor tissues. Stabilization/activation of hypoxia-
inducible factor I is the key cellular response under
hypoxic conditions. Hypoxia-inducible factor I
acts as a transcription regulator that controls ex-
pression of a wide variety of genes, including
HLA-G in response to hypoxia. Gazit et al have
recently demonstrated that hypoxia upregulates
HLA-G in Epstein–Barr-virus-transformed B-cell
lines but not in freshly isolated peripheral blood
lymphocytes, which suggests that oncogenic
viruses also play a role in hypoxia-induced HLA-G
upregulation.37
A tumor microenvironment is enriched by a
variety of cytokines that are released by tumor-
infiltrating lymphocytes. The interaction of 
cytokines and tumor cells can regulate HLA-G ex-
pression. For example, granulocyte–macrophage
colony-stimulating factor and interferon (IFN)-γ
that are secreted by infiltrating cytotoxic T cells
have been shown to enhance HLA-G expression 
in tumor cells.38 Secretion of interleukin (IL)-10
by tumor cells can also upregulate HLA-G expres-
sion in tumor tissues through an autocrine or
paracrine mechanism.9,39 HLA-G, in turn, modu-
lates cytokine expression in immune cells to pro-
duce a profile of Th2-type cytokines, including
IL-10, IL-4 and IL-3. Clinical studies have shown
that this shift towards the Th2 cytokine profile,
especially the enhanced IL-10 secretion, is fre-
quently associated with impairment of antitumor
immunity.
Molecular Mechanisms of HLA-G in
Immunosuppression
Tumor development and progression are always
accompanied by expression of novel tumor-
associated antigens that can elicit an immune 
reaction by activating immune defenders such as
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cytotoxic T cells, natural killer (NK) cells, and
macrophages. In recent decades, great efforts have
been made to develop immunotherapy against
cancer by applying tumor-specific cytotoxic T-cells
to cancer patients.40 Although this T-cell-based
approach has shown some promise in preclinical
models and clinical trials, only moderate success
has been achieved to date.41 Tumor clones equip-
ped with the ability to evade immune recogni-
tion and destruction undergo clonal expansion,
which ultimately leads to tumor recurrence that
is refractory to the previous immunotherapy.
One of the possible mechanisms that cancer
cells employ to overcome vigilant immunosur-
veillance and hostile attack involves expression
of HLA-G. A growing body of evidence has dem-
onstrated that direct interaction between HLA-G
and leukocyte immunoglobulin-like receptors,
LILRB1 (also known as LIR1/ILT2/CD85J) and
LILRB2 (LIR2/ILT4/CD85D), and between HLA-G
and KIR2DL4 (CD158D).42,43 LILRB1 and LILRB2
belong to a family of immunoreceptors that are
expressed on T cells, B cells, monocytes (macro-
phages), myeloid dendritic cells (DCs), and NK
cells, which upon ligand binding can inactivate
those immune effectors.44 On the other hand,
KIR2DL4 belongs to the gene family of killer 
cell inhibitory receptors, which upon binding to
HLA-G inhibit NK-cell-mediated cytolytic activ-
ity.45 Although these immunoglobulin-like recep-
tors also interact with other HLA class I ligands,
they show the highest binding affinity to HLA-G.46
HLA-G-binding ligands share a common cyto-
plasmic immunoreceptor tyrosine-based inhib-
itory motif sequence, which upon HLA-G binding
can recruit intracellular protein-tyrosine phos-
phatases and trigger an inhibitory signal cascade.
The negative signaling, in turn, downregulates the
activation of various immunoresponsive genes and
affects the cytokine/chemokine profiles secreted
by the effector cells. As a result, cell maturation
and clonal expansion of immunocompetent cells
are significantly reduced. Membrane-bound and
secreted forms of HLA-G are capable of upregu-
lating the expression levels of its binding ligands,
the immunoglobulin-like inhibitory receptors.47
Therefore, these effector cells become more sen-
sitive to the HLA-G-mediated inhibitory effects,
which results in immune tolerance of tumor
cells.
Tumor immunology consists of complex dia-
log between cancer cells and a variety of resident
immune effectors within the tumor microenviron-
ment. In the following sections, we briefly sum-
marize the receptors that are known to interact
with HLA-G, and the biological effects of HLA-G
on immune cells, including T-lymphocytes, NK
cells, DCs, and B-lymphocytes (Figure 2).
Interactions with T lymphocytes
In cell-mediated immunity, the interaction be-
tween antigen-presenting cells and T cells is a
crucial step in activating antigen-specific CD4+
T cells. The activated CD4+ T cells differentiate
into CD4+ T helper cells that can trigger activa-
tion and differentiation of CD8+ T cells into cyto-
toxic T cells. It is known that tumor antigen can
be presented by tumor cells in the form of HLA/
peptide complexes. However, T-cell-mediated tu-
mor rejection does not occur when tumor cells
express HLA-G. Studies with tumor tissues and
cell lines have demonstrated that HLA-G-positive
or HLA-G-transfected tumor cells are less suscep-
tible to recognition by CD4+ T cells and cytolytic
killing by CD8+ cells.10,48 How this can occur has
intrigued investigators for a long time, and it has
now become clear that several mechanisms are
involved in HLA-G-induced inactivation of T-cell
immunity. For example, it has been reported that
interaction between HLA-G and CD4+ T cells 
via LILRB1 and LILRB2 can reduce production of 
T-helper 1 (Th1) cytokines including IFN-γ, IL-2
and tumor necrosis factor-α but enhance pro-
duction of Th2 cytokines including IL3, IL-4 and
IL-10,49–51 which results in inactivation of cyto-
toxic T cells and reduction of antitumor antibody
secretion.
sHLA-G can also bind to CD8 and induce
apoptosis through activation of the Fas/FasL path-
way.52–55 Bahri et al have reported that HLA-G
can block cell cycle progression from G1 to G2/M
phase in T cells.56 A recent study has indicated
HLA-G and immune evasion in cancer cells
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that HLA-G1-transfected antigen-presenting cells
can reduce CD4+ T-cell proliferation by inducing
T-cell anergy or long-term unresponsiveness.57
Other studies have demonstrated that immune
tolerance mediated by HLA-G molecules can be
achieved by induction of immunosuppressive/
regulatory T cells.57–60 These cells have been found
to reduce T-cell activation and promote T-cell
death, thus facilitating immunosuppression and
long-term immune evasion or tolerance. Finally,
HLA-G expression can also abolish cytotoxic-
T-cell-mediated cell lysis through interaction of
HLA-E and the CD94/NKG complex. These events
lead to almost complete abortion of the immune
responses, and as a result, tumor cells are pro-
tected from T cell attack.
Interactions with NK cells
NK cells are responsible for detecting and elim-
inating cells that are undergoing malignant
transformation. Engineered expression of HLA-G
protein in MHC-class-I negative cells has been
demonstrated to inhibit cytolysis by NK cells.61–63
LIR-2 and KIR2DL4 on the cell surface of NK
cells appear as the main inhibitory receptors 
that interact with HLA-G, and both receptors,
upon HLA-G binding, are thought to mediate in-
hibitory effects on NK cells. Furthermore, HLA-G
might indirectly contribute to suppression of
NK-cell-mediated cytolysis through upregulation
of HLA-E.64 Besides, sHLA-G has been shown to be
involved in producing pro-angiogenic cytokines
in NK cells through KIR2DL4,65 which could con-
tribute indirectly to tumor development.
Interactions with DCs
DCs play a central role in regulating immune 
responses and maintaining peripheral toler-
ance.41,66,67 Previous reports have shown that 
the interaction between HLA-G and its receptors
Figure 2. Molecular mechanisms for how cancer cells downregulate immunosurveillance by expressing HLA-G. HLA-G
exerts negative immunoregulatory functions by interacting with leukocyte immunoglobulin-like inhibitory receptors
(LILRB1 or LILRB2) or killer cell immunoglobulin-like receptor (KIR2DL4) on a range of immune effector cells, including
T cells, natural killer cells, dendritic cells and B cells. Monomeric and dimeric HLA-G can inactivate/anergize the immune
effector cells, whereas dimerization of HLA-G can enhance the binding affinity toward the immunoglobulin-like receptors
and stabilize the binding complex.
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(LILRB1 and LILRB2) on DCs results in inactiva-
tion of the MHC class II presentation pathway
and downregulation of co-stimulatory molecules,
B7.1 (CD80) and B7.2 (CD86).58,59,68 IL-12 pro-
duction and chemokine receptor CCR7 expres-
sion on these targeted DCs are also significantly
inhibited. All the above effects lead to suppres-
sion of DC maturation, which can further con-
tribute to failure or unresponsiveness of T-cell
activation and clone expansion in response to
tumor-antigen stimulation.
Interactions with B cells
The major function of B cells is to generate and
secret antibodies that directly target novel solu-
ble antigens or antigens on abnormal cells, thus
playing a central role in adaptive humoral immu-
nity. Until now, there has been a lack of evidence
to show the direct interaction between HLA-G and
the surface of B cells. However, the possibility of
such interaction exists because of the presence 
of LILRB1 and LILRB2 on B cells. The biological
effects of HLA-G in modulating B-cell functions
in human cancer remain to be determined.
New Treatments and Therapeutics
Against HLA-G Expression
Since HLA-G expression in tumor tissues is a
unique feature that negatively correlates with
clinical outcomes, HLA-G accordingly becomes
an attractive target for developing new interven-
tions against more invasive and metastatic cancer
cells. Given the fact that the main inhibitory 
effects of HLA-G are mediated by its interaction
with lymphocyte immunoglobulin-like receptors,
blocking the reaction by antagonistic recombinant
proteins or neutralizing antibodies should be
beneficial for treating HLA-G-expressing cancer
cells. By in vitro allostimulation assays, antibodies
against LIR-1 and LIR-2 have successfully restored
T-cell proliferation, which indicates the effective-
ness of such a therapeutic approach. Similar re-
sults can also be found when treating cancer 
cells with anti-FasL antibodies that block the
Fas/FasL pathway through binding of HLA-G to
LIR-1 or LIR-2. These data support a potential
application of using HLA-G blockers, such as
HLA-G neutralizing antibodies or soluble recom-
binant LILRB1, LIR-2 or Fas, as therapeutic agents
to minimize the inhibitory effects of HLA-G
molecules.
Conversely, sHLA-G serves as an ideal bio-
marker for cancer detection in body fluids.28 The
value of HLA-G expression in predicting clinical
outcome in certain cancers and the HLA-G tests
(e.g. immunohistochemistry or quantitative real-
time polymerase chain reaction) are expected 
to provide oncologists with a new molecular ap-
proach to manage their cancer patients better.28
Anti-HLA-G antibodies could also be utilized for
developing a cancer imaging system to monitor
the activity and location of tumor cells that have
been tolerated by the immune defense system.
Target-based chemotherapy can be achieved by
using antibody delivery methods to bring the 
cytotoxic drugs to the more aggressive tumor 
tissues. Small interfering RNA/small hairpin
RNA therapies could be also applied to HLA-G-
expressing cells by this antibody-oriented route.
Furthermore, enhancing the Th1 cytokine profile
in the host by boosting more potent immuno-
modulators or by immunization with cancer 
vaccine might also be feasible for changing the
microenvironment to reactivate host immune
surveillance. More studies need to be conducted
to evaluate the efficacy of each method in clini-
cal applications.
Several anticancer drugs have been found to be
inducers for cancer cells to express higher levels
of HLA-G proteins, which results in tumor eva-
sion of the host immune system. For example, 
5-aza-2’-deoxycytidine, a demethylating agent for
treating cancer patients during epigenetic therapy,
could reactivate expression of HLA-G protein in
all the cell lines tested. Similarly, IFN immuno-
therapy of malignant tumors can cause side effects
of immune evasion by upregulating the expres-
sion of HLA-G at the tumor sites. Screening of
tumor lesions for HLA-G expression might repre-
sent a useful strategy to identify the patients who
HLA-G and immune evasion in cancer cells
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are likely to benefit from epigenetic and IFN
therapy.
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